News
BRIEF-First Patient Treated In Mapi Pharma's Phase II Clinical Trial Of ...
www.reuters.com
Jan 30 (Reuters) - Mapi Pharma Ltd: * FIRST PATIENT TREATED IN MAPI PHARMA'S PHASE II CLINICAL TRIAL OF GA DEPOT FOR ...
First Patient Treated in Mapi Pharma’s Phase IIa Clinical Trial of...
article.wn.com
GA Depot is a long-acting depot formulation injection of Glatiramer Acetate given once a month rather than daily or thrice weekly as in the.
Mapi Pharma Treats 1st RRMS Patient with Once-A-Month GA Depot
multiplesclerosisnewstoday.com
Read more about Mapi Pharma Treats 1st RRMS Patient with Once-A-Month GA Depot, an experimental injectable, reported better than Copaxone®.
Mapi Pharma begins phase IIa study of GA Depot to treat RRMStest.pharmabiz.com › news › mapi-pharma-begins-phase-iia-study-of-ga-de...
test.pharmabiz.com
GA Depot is a long-acting depot formulation injection of Glatiramer Acetate given once a month rather than daily or thrice weekly as in the case of Copaxone. GA ...
sorted by relevance / date